Anekant Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 15-12-2024
- Paid Up Capital ₹ 0.55 M
as on 15-12-2024
- Company Age 7 Year, 10 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 1.10 Cr
as on 15-12-2024
- Revenue 54.32%
(FY 2021)
- Profit 7.89%
(FY 2021)
- Ebitda -0.13%
(FY 2021)
- Net Worth 97.65%
(FY 2021)
- Total Assets 185.99%
(FY 2021)
About Anekant Pharmaceuticals
The Corporate was formerly known as Seramejor Technologies Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 0.55 M.
The company currently has active open charges totaling ₹1.10 Cr.
Anil Kumar, Motilal Chawla, Ashish Singh, and Two other members serve as directors at the Company.
- CIN/LLPIN
U36100DL2017PTC311457
- Company No.
311457
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Feb 2017
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Anekant Pharmaceuticals?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Kumar  | Director | 01-May-2023 | Current |
| Motilal Chawla | Director | 01-May-2023 | Current |
| Ashish Singh | Director | 31-Jul-2020 | Current |
| Pankaj Jain | Additional Director | 10-Oct-2021 | Current |
| Jai Aggarwal | Director | 31-Jul-2020 | Current |
Financial Performance and Corporate Structure Insights of Anekant Pharmaceuticals.
Anekant Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 54.32% increase. The company also saw a slight improvement in profitability, with a 7.89% increase in profit. The company's net worth Soared by an impressive increase of 97.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Anekant Pharmaceuticals?
In 2021, Anekant Pharmaceuticals had a promoter holding of 76.67% and a public holding of 23.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 03 Feb 2021 | ₹1.10 Cr | Open |
How Many Employees Work at Anekant Pharmaceuticals?
Unlock and access historical data on people associated with Anekant Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Anekant Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Anekant Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
